Kyle Leeman

Kyle Leeman has extensive experience in analytical research and development within the pharmaceutical industry. Currently serving as the Executive Director of Analytical Development and QC at Iambic Therapeutics, responsibilities include overseeing analytical development, method transfers, and quality control for pre-clinical and clinical products. Prior to this role, Kyle was the Vice President of Analytical Research & Development and Quality Control at Mirati Therapeutics, where strategic vision for drug substance and drug product support was driven. Previous positions include Executive Director of Analytical Development at Neurocrine Biosciences, leading analytical activities for significant commercial products, and various roles at Pfizer, where project-related analytical activities in a cGMP environment were coordinated. Education includes a Bachelor of Science in Chemistry from Quinnipiac University.